Global Patent Index - EP 1864668 A1

EP 1864668 A1 20071212 - Use of prodrugs for ocular intravitreous administration

Title (en)

Use of prodrugs for ocular intravitreous administration

Title (de)

Verwendung von Arzneimittelpräkursor für okuläre intravitrealen Verabreichung

Title (fr)

Utilisation de promédicaments pour une administration oculaire intravitréenne

Publication

EP 1864668 A1 20071212 (EN)

Application

EP 06290902 A 20060601

Priority

  • EP 06290902 A 20060601
  • US 44433706 A 20060601
  • EP 06290901 A 20060601
  • US 44434906 A 20060601

Abstract (en)

Use of a composition comprising at least one prodrug of a steroid, preferably of a corticosteroid, for the preparation of an ophthalmic composition intended for the treatment of an ocular condition or disease of a human being or an animal.

IPC 8 full level

A61K 31/573 (2006.01); A61K 47/48 (2006.01); A61P 27/00 (2006.01); A61P 27/02 (2006.01)

CPC (source: EP KR US)

A61K 9/0014 (2013.01 - EP US); A61K 9/0048 (2013.01 - EP US); A61K 31/4745 (2013.01 - EP US); A61K 31/573 (2013.01 - EP KR US); A61K 47/543 (2017.07 - EP US); A61P 27/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 31/04 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 43/00 (2017.12 - EP); A61K 48/00 (2013.01 - EP US)

Citation (applicant)

  • WEIJTENS, OPHTHALMOLOGY, 2002
  • WEIJTENS, AM J OPHTHALMOL, 1998
  • WEIJTENS ET AL., OPHTHALMOLOGY, 2000
  • KWAK, ARCH OPHTHALMOL, 1992
  • AM J OPHTHALMOL, 2005
  • JAFFE, OPHTHALMOLOGY, 2005
  • PEARSON, ISOPT COMMUNICATION, 2006
  • WILLIAMS, ISOPT COMMUNICATION, 2006
  • TAN, OPHTHALMOLOGY, 2004
  • BUI QUOC, J FR OPHTALMOL, 2002

Citation (search report)

  • [X] US 2006094700 A1 20060504 - LYONS ROBERT T [US]
  • [X] WO 2004058272 A1 20040715 - CONTROL DELIVERY SYS INC [US], et al
  • [Y] WO 9911270 A1 19990311 - PHARMATEAM DEV LTD [IL], et al
  • [Y] CHENG LINGYUN ET AL: "Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. NOV 2004, vol. 45, no. 11, November 2004 (2004-11-01), pages 4138 - 4144, XP002409157, ISSN: 0146-0404
  • [Y] CHENG LINGYUN ET AL: "Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phos pho-ganciclovir.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. FEB 2002, vol. 43, no. 2, February 2002 (2002-02-01), pages 515 - 521, XP002409158, ISSN: 0146-0404
  • [X] TASKINTUNA I ET AL: "Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis.", RETINA (PHILADELPHIA, PA.) 1997, vol. 17, no. 1, 1997, pages 57 - 64, XP009074806, ISSN: 0275-004X
  • [X] SCHMIDT LAUGESEN CAROLINE ET AL: "Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs.", ACTA OPHTHALMOLOGICA SCANDINAVICA. APR 2005, vol. 83, no. 2, April 2005 (2005-04-01), pages 184 - 190, XP002409159, ISSN: 1395-3907
  • [X] YANG C-S ET AL: "AN INTRAVITREAL SUSTAINED-RELEASE TRIAMCINOLONE AND 5-FLUOROURACIL CODRUG IN THE TREATMENT OF EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY", ARCHIVES OF OPHTHALMOLOGY, vol. 116, no. 1, January 1998 (1998-01-01), pages 69 - 77, XP008001871, ISSN: 0003-9950
  • [A] MACHA SREERAJ ET AL: "Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis.", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS. JUN 2002, vol. 30, no. 6, June 2002 (2002-06-01), pages 670 - 675, XP002409160, ISSN: 0090-9556

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

EP 1864667 A1 20071212; EP 1864667 B1 20130904; AU 2007267079 A1 20071206; AU 2007267079 B2 20130131; CA 2653902 A1 20071206; CA 2653902 C 20150317; CN 101553235 A 20091007; CN 101553235 B 20121205; DK 1864668 T3 20130304; DK 2319517 T3 20131209; EP 1864668 A1 20071212; EP 1864668 B1 20121121; EP 2319517 A1 20110511; EP 2319517 B1 20130911; EP 2322183 A1 20110518; EP 2322183 B1 20141022; ES 2399976 T3 20130404; HK 1110219 A1 20080711; HK 1110221 A1 20080711; IL 195626 A0 20090901; IL 195626 A 20170529; JP 2009538879 A 20091112; JP 2009538880 A 20091112; JP 5284953 B2 20130911; JP 5455624 B2 20140326; KR 101408317 B1 20140617; KR 20090031373 A 20090325; PL 1864667 T3 20140131; PL 1864668 T3 20130430; PL 2319517 T3 20140131; PL 2322183 T3 20150130; PT 1864667 E 20131118; PT 1864668 E 20130226; SI 1864668 T1 20130430; US 2007280902 A1 20071206; US 2007280995 A1 20071206; US 2007281913 A1 20071206; US 2007281914 A1 20071206; US 8227452 B2 20120724; US 9192567 B2 20151124; WO 2007138113 A1 20071206; WO 2007138114 A1 20071206

DOCDB simple family (application)

EP 06290901 A 20060601; AU 2007267079 A 20070601; CA 2653902 A 20070601; CN 200780020172 A 20070601; DK 06290902 T 20060601; DK 10177382 T 20060601; EP 06290902 A 20060601; EP 10177375 A 20060601; EP 10177382 A 20060601; EP 2007055413 W 20070601; EP 2007055414 W 20070601; ES 06290902 T 20060601; HK 08104425 A 20080421; HK 08104540 A 20080423; IL 19562608 A 20081201; JP 2009512616 A 20070601; JP 2009512617 A 20070601; KR 20087031197 A 20070601; PL 06290901 T 20060601; PL 06290902 T 20060601; PL 10177375 T 20060601; PL 10177382 T 20060601; PT 06290901 T 20060601; PT 06290902 T 20060601; SI 200631521 T 20060601; US 44433706 A 20060601; US 44434906 A 20060601; US 80655407 A 20070601; US 80655607 A 20070601